ASCO GU 2021: New standard of care recommended for upper tract urothelial cancer
The Institute of Cancer Research in the UK found that the implementation of gemcitabine-platinum...
Read More
ASCO GU 2021
Results from Phase 3 CLEAR Study for Advanced RRC
In patients with advanced RCC, second-line treatment with LEN + EVE prolonged progression-free survival (PFS) compared with EVE alone. LEN + PEMBRO, also showed preliminary efficacious evidence in a phase 1/2 RCC study. Here, we...
Read MoreASCO GU 2021 Kicks Off! What to Expect
The 2021 Genitourinary (GU) Cancers Symposium, one of the largest conference in genitourinary cancers will be held virtually February 11 to 13, showcasing practice-changing research, diverse speakers, global perspectives, and...
Read MorePhase 3 TITAN: Overall Survival Benefit and Safety in Advanced Prostate Cancer
Treatment with apalutamide Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer Final analysis from Phase 3 TITAN study demonstrated apalutamide provided statistically...
Read MoreASCO GU 2021: Adding to the Armamentarium of Therapy for Bladder Cancer
In high-risk muscle-invasive urothelial carcinoma, the use of nivolumab after surgery cut patients’ risk of disease returning or death by 30% over placebo. The data was released for presentation at the American Society of...
Read MoreData on Cabozantinib Activity in Brain Metastases in RCC
Results from a retrospective analysis evaluating (cabozantinib) activity in brain metastases in patients with renal cell carcinoma (RCC) will be presented as part of the Poster Session: Renal Cell Cancer at the 2021 American...
Read MorePhysQuiz Answers! ASCO GU: Renal Cell Carcinoma
1) Results released from the Phase 3 CLEAR Trial found that lenvatinib combined with EITHER of these two drugs demonstrated significant benefits over sunitinib in patients with advanced RCC: a) pembrolizumab or...
Read More- 1
- 2